U.S. gene therapy company Passage Bio has launched $115.5 million Series A financing.
The round was conducted by U.S. healthcare-dedicated investment firm OrbiMed Advisors with participation from Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.
With the net capital raised, Passage Bio will develop a portfolio of five therapeutic candidates to treat rare monogenic central nervous system diseases.
Further, Passage Bio will also finance the preclinical development of up to seven extra rare monogenic central nervous system indication programs, license new intellectual property arising from the programs.